- Home
- PCTY vs ABVX Comparison
PCTY vs ABVX Comparison
Compare PCTY & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCTY | ABVX |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.2B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCTY | ABVX |
|---|---|---|
| Price | $145.65 | $122.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | ★ $203.88 | $130.09 |
| AVG Volume (30 Days) | 523.5K | ★ 1.8M |
| Earning Date | 02-05-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.58 | N/A |
| EPS | ★ 4.00 | N/A |
| Revenue | ★ $1,640,437,000.00 | $6,231,374.00 |
| Revenue This Year | $10.71 | $6.80 |
| Revenue Next Year | $7.98 | N/A |
| P/E Ratio | $36.84 | ★ N/A |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $135.46 | $4.77 |
| 52 Week High | $223.80 | $148.83 |
Technical Indicators
Market Signals| Indicator | PCTY | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 50.83 |
| Support Level | $137.15 | $113.64 |
| Resistance Level | $148.70 | $122.50 |
| Average True Range (ATR) | 4.55 | 8.45 |
| MACD | -0.54 | -0.57 |
| Stochastic Oscillator | 47.22 | 58.34 |
Price Performance
Historical ComparisonAbout PCTY Paylocity Holding Corporation
Founded in 1997, Paylocity is a cloud-based human capital management and payroll platform servicing midmarket customers. The company's average client size is around 150 employees. Its products help with recruiting and onboarding, payroll, time and labor, human resources, benefits, learning, and performance and compensation workflows. In fiscal 2025, the company generated over $1.5 billion in revenue across more than 41,000 customers.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.